These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23076343)

  • 1. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
    Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
    J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the binding of cis/trans-[MCl4(1H-indazole)(NO)](-) (M = Ru, Os) complexes to human serum albumin.
    Dömötör O; Rathgeb A; Kuhn PS; Popović-Bijelić A; Bačić G; Enyedy EA; Arion VB
    J Inorg Biochem; 2016 Jun; 159():37-44. PubMed ID: 26908285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis(imidazol)ruthenate(III)].
    Trynda-Lemiesz L; Keppler BK; Kozłowski H
    J Inorg Biochem; 1999 Mar; 73(3):123-8. PubMed ID: 10331241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
    Cetinbas N; Webb MI; Dubland JA; Walsby CJ
    J Biol Inorg Chem; 2010 Feb; 15(2):131-45. PubMed ID: 19707803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III).
    Trynda-Lemiesz L; Karaczyn A; Keppler BK; Kozłowski H
    J Inorg Biochem; 2000 Mar; 78(4):341-6. PubMed ID: 10857915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
    Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
    Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
    Bytzek AK; Boeck K; Hermann G; Hann S; Keppler BK; Hartinger CG; Koellensperger G
    Metallomics; 2011 Oct; 3(10):1049-55. PubMed ID: 21935553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
    Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
    J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
    Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
    J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
    Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
    Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
    Kratz F; Hartmann M; Keppler B; Messori L
    J Biol Chem; 1994 Jan; 269(4):2581-8. PubMed ID: 8300587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.